{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:42:20Z","timestamp":1793814140217,"version":"4.6.1"},"reference-count":29,"publisher":"Society of Nuclear Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,4,24]]},"DOI":"10.2967\/jnumed.125.269913","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T19:00:35Z","timestamp":1747940435000},"page":"jnumed.125.269913","source":"Crossref","is-referenced-by-count":7,"title":["<sup>177<\/sup>Lu-PSMA-617 Consolidation Therapy After Docetaxel in Patients with Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Randomized, Phase 2 Trial"],"prefix":"10.2967","author":[{"given":"Swayamjeet","family":"Satapathy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandan K.","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikha","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwani","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kannan","family":"Periasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyush","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komal","family":"Preet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrawan K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravimohan S.","family":"Mavuduru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girdhar S.","family":"Bora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya P.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajender","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harmandeep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagwant R.","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"2025052212001001000_jnumed.125.269913v1.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00651-2"},{"key":"2025052212001001000_jnumed.125.269913v1.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214122"},{"key":"2025052212001001000_jnumed.125.269913v1.3","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-020-00119-z"},{"key":"2025052212001001000_jnumed.125.269913v1.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.3921"},{"key":"2025052212001001000_jnumed.125.269913v1.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.11.021"},{"key":"2025052212001001000_jnumed.125.269913v1.6","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/JU.0000000000004158","article-title":"Early prostate-specific antigen response by 6 months is predictive of treatment effect in metastatic hormone sensitive prostate cancer: an exploratory analysis of the TITAN trial","volume":"212","author":"Roy","year":"2024","journal-title":"J Urol."},{"key":"2025052212001001000_jnumed.125.269913v1.7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1200\/JCO.2025.43.5_suppl.167","article-title":"Impact of PSA nadir on long-term survival in metastatic hormone-sensitive prostate cancer: final 10-year analysis of the ECOG-ACRIN E3805 CHAARTED trial [abstract]","volume":"43","author":"Tripathi","year":"2025","journal-title":"J Clin Oncol."},{"key":"2025052212001001000_jnumed.125.269913v1.8","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/oncolo\/oyac279","article-title":"PSMA-targeted radiopharmaceuticals in prostate cancer: current data and new trials","volume":"28","author":"Ramnaraign","year":"2023","journal-title":"Oncologist."},{"key":"2025052212001001000_jnumed.125.269913v1.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2025052212001001000_jnumed.125.269913v1.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00237-3"},{"key":"2025052212001001000_jnumed.125.269913v1.11","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1007\/s00259-021-05618-3","article-title":"177Lu-PSMA-617 versus docetaxel in chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial","volume":"49","author":"Satapathy","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025052212001001000_jnumed.125.269913v1.12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266141"},{"key":"2025052212001001000_jnumed.125.269913v1.13","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet."},{"key":"2025052212001001000_jnumed.125.269913v1.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503747"},{"key":"2025052212001001000_jnumed.125.269913v1.15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2214\/AJR.18.20845","article-title":"Radioligand therapy with 177Lu-PSMA for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"213","author":"Yadav","year":"2019","journal-title":"AJR."},{"key":"2025052212001001000_jnumed.125.269913v1.16","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s00259-017-3895-x","article-title":"Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review","volume":"45","author":"von Eyben","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025052212001001000_jnumed.125.269913v1.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2025052212001001000_jnumed.125.269913v1.18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"2025052212001001000_jnumed.125.269913v1.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00367-1"},{"key":"2025052212001001000_jnumed.125.269913v1.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119115"},{"key":"2025052212001001000_jnumed.125.269913v1.21","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.3390\/cancers16132331","article-title":"Is there an opportunity to de-escalate treatments in selected patients with metastatic hormone-sensitive prostate cancer?","volume":"16","author":"G\u00f3mez-Aparicio","year":"2024","journal-title":"Cancers (Basel)."},{"key":"2025052212001001000_jnumed.125.269913v1.22","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.eururo.2021.06.012","article-title":"Short-course 177Lu-PSMA-617 radioligand therapy in high-volume metastatic hormone-sensitive prostate cancer: time to take the leap?","volume":"80","author":"Satapathy","year":"2021","journal-title":"Eur Urol."},{"key":"2025052212001001000_jnumed.125.269913v1.23","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/RLU.0000000000005000","article-title":"Promising therapeutic activity of 177Lu-PSMA-617 in synchronous high-volume metastatic hormone-sensitive prostate cancer: a pilot experience","volume":"49","author":"Satapathy","year":"2024","journal-title":"Clin Nucl Med."},{"key":"2025052212001001000_jnumed.125.269913v1.24","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","article-title":"Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study","volume":"25","author":"Azad","year":"2024","journal-title":"Lancet Oncol."},{"key":"2025052212001001000_jnumed.125.269913v1.25","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (Enza-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol."},{"key":"2025052212001001000_jnumed.125.269913v1.26","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1470-2045(25)00009-9","article-title":"Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (Enza-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial","volume":"26","author":"Emmett","year":"2025","journal-title":"Lancet Oncol."},{"key":"2025052212001001000_jnumed.125.269913v1.27","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268640"},{"key":"2025052212001001000_jnumed.125.269913v1.28","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II: 2024 update\u2014treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur Urol."},{"key":"2025052212001001000_jnumed.125.269913v1.29","doi-asserted-by":"crossref","first-page":"S1162","DOI":"10.1016\/j.annonc.2022.07.1493","article-title":"8-month PSA strongly predicts outcomes of men with metastatic castration-sensitive prostate cancer in the PEACE-1 phase III trial","volume":"33(suppl 7)","author":"Mescam","year":"2022","journal-title":"Ann Oncol."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.269913","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T19:00:38Z","timestamp":1747940438000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.269913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":29,"alternative-id":["10.2967\/jnumed.125.269913"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.269913","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]}}}